Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Gastrointestinal Agents

Gemcitabine

Pancrelipase

Pancreatin

Antimetabolites

Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.

Pazopanib 800 mg PO daily of each 28 day cycle.

Pazopanib

Joel Picus, M.D.

To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.

To determine the response rate by RECIST criteria.

To determine the progression free survival.

To determine the median survival and overall survival at one year.

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

A Phase II Study of Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

* Response rate = complete response + partial response per RECIST
* Complete response - disappearance of all target and non-target lesions.
* Partial response - at least a 30% decrease in the sum of the longest diameter of the target lesions, taking as reference the baseline sum longest diameter

* PFS is defined as the duration of time from start of treatment to time to progression.
* Progressive disease - at least a 20% increase in the sum of the longest diameter of the target lesions taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.

Washington University School of Medicine

Arm 1 (Gemcitabine & Pazopanib)

Age, Categorical

Sex: Female, Male

United States

Region of Enrollment

One participant was removed from study for adverse event prior to first response assessment. The remaining participant had progressive disease per RECIST while on treatment.

Response Rate by RECIST Criteria.

One participant was removed from study for adverse event prior to first response assessment.

Progression-free Survival (PFS)

Median Survival

Overall Survival

Overall Study

Spots Global Cancer Trial Database for Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial